U.S. markets close in 3 hours 2 minutes

Grifols, S.A. (GRF.MC)

MCE - MCE Precio retrasado. Divisa en EUR.
Añadir a la lista de seguimiento
8.08-0.89 (-9.96%)
Al cierre: 05:42PM CET

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 93 571 05 00
https://www.grifols.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - General
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Thomas H. GlanzmannCEO & Executive Chairman150kN/D1958
Mr. Alfredo Arroyo GuerraCFO & VPN/DN/D1958
Mrs. Eva Bastida TubauCorporate Vice President and Director of Scientific & Medical AffairsN/DN/DN/D
Ms. Nuria Pascual LapeñaVP of Corporate Treasury, Risk Management Investor Relation & Sustainability OfficerN/DN/D1964
Mr. David Ian BellChief Corporate Development, Legal & Data Protection OfficerN/DN/D1954
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/DN/D1965
Ms. Montserrat Gaja LlamasChief Human Resources OfficerN/DN/D1965
Mr. Vicente Blanquer TorreChief Quality OfficerN/DN/D1961
Mr. Alberto Grifols RouraPresident of the Bio Supplies DivisionN/DN/D1959
Mr. Sergio Roura AdellPresident of Commercial Tech SupportN/DN/D1968
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Gestión corporativa

La calificación ISS Governance QuickScore de Grifols, S.A. a partir del 1 de marzo de 2024 es 4. Las puntuaciones principales son Auditoría: 2; Junta: 5; Derechos del accionista: 9; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.